What are the roles of global DNA and APC 2 gene promotor hypermethylation in multiple myeloma?

Basit Öğe Kaydı
dc.authoridSERIN, Istemi / 0000-0003-1855-774X
dc.contributor.authorPehlivan, Sacide
dc.contributor.authorSerin, Istemi
dc.contributor.authorNursal, Ayse Feyda
dc.contributor.authorOyaci, Yasemin
dc.contributor.authorGundes, Ilknur
dc.contributor.authorPehlivan, Mustafa
dc.date.accessioned2021-11-01T15:06:00Z
dc.date.available2021-11-01T15:06:00Z
dc.date.issued2021
dc.department[Belirlenecek]
dc.description.abstractBackground In today's practice, gene-based approaches come to the fore in the determination of prognosis and treatment preferences of multiple myeloma (MM). DNA methylation is one of the new approach parameters. DNA methylation occurs by the addition of a methyl group to cytosines in CpG dinucleotides. In this study, besides comparing the global DNA and APC 2 gene promotor hypermethylation between our patients with MM and healthy control group, we aimed to demonstrate the effect of hypermethylation on MM treatment responses and survival. Methods and results 38 patients diagnosed with MM between January 2016 and January 2020 and 50 healthy controls were included in the study. The initial hypermethylation of the patients and the healthy control group were statistically analyzed. In addition, the increase in hypermethylation in the MM group before and after the first series of treatments were analyzed within themselves. There is a significant difference between the patients with MM diagnosis and the healthy control group in terms of the initial global hypermethylation (P = 0.001). In patients with MM, hypermethylation was significantly higher. Global hypermethylation in the post-treatment measurements was significantly increased in comparison to the pre-treatment state (P = 0.012). In terms of APC 2 promotor gene-specific hypermethylation, no significant differences were detected between pre- and post-treatment values (P = 0.368). Conclusions This study represents valuable data with the initial global DNA hypermethylation results in the MM patient group and the increase in hypermethylation post-treatment. it will shed light on future studies.
dc.identifier.doi10.1007/s11033-021-06813-z
dc.identifier.issn0301-4851
dc.identifier.issn1573-4978
dc.identifier.pmid34637096
dc.identifier.scopus2-s2.0-85116904934
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1007/s11033-021-06813-z
dc.identifier.urihttps://hdl.handle.net/11491/7462
dc.identifier.wosWOS:000706551300008
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthor[Belirlenecek]
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofMolecular Biology Reports
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectMultiple myelomaen_US
dc.subjectDNA methylationen_US
dc.subjectTreatmenten_US
dc.subjectResponseen_US
dc.subjectSurvivalen_US
dc.titleWhat are the roles of global DNA and APC 2 gene promotor hypermethylation in multiple myeloma?
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu